Alphabet Inc’s Arcus Biosciences RCUS Stock Holding History

Alphabet Inc’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,563,441	Closed	-$80.9M	–	59
2022 Q1	$80.9M	Hold	2,563,441	–	–	2.63%	10
2021 Q4	$104M	Sell	2,563,441 -1,537,034	-37%	-$59.6M	2.51%	12
2021 Q3	$143M	Sell	4,100,475 -513,343	-11%	-$16M	3.39%	8
2021 Q2	$127M	Sell	4,613,818 -109,530	-2%	-$3.13M	2.58%	7
2021 Q1	$133M	Sell	4,723,348 -326,438	-6%	-$11.4M	5.35%	5
2020 Q4	$131M	Hold	5,049,786	–	–	6.29%	5
2020 Q3	$86.6M	Hold	5,049,786	–	–	4.07%	4
2020 Q2	$125M	Hold	5,049,786	–	–	5.77%	5
2020 Q1	$70.1M	Hold	5,049,786	–	–	4.6%	5
2019 Q4	$51M	Hold	5,049,786	–	–	3.08%	5
2019 Q3	$46M	Hold	5,049,786	–	–	1.38%	4
2019 Q2	$40.1M	Hold	5,049,786	–	–	0.76%	6
2019 Q1	$63.1M	Hold	5,049,786	–	–	3.26%	4
2018 Q4	$54.4M	Hold	5,049,786	–	–	6.43%	4
2018 Q3	$70.4M	Hold	5,049,786	–	–	6.74%	5
2018 Q2	$61.8M	Hold	5,049,786	–	–	5.19%	5
2018 Q1	$78M	Buy	+5,049,786	New	+$84.1M	12.68%	3

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alphabet Inc's RCUS Position: Q2 2022 in Review

Alphabet Inc sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 2,563,441 shares — an estimated $80.9M sold.

Alphabet Inc first reported a position in RCUS in Q1 2018 and held it in 17 quarters. The position peaked at $143M in Q3 2021. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

Alphabet Inc reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
Alphabet Inc sold 2,563,441 Arcus Biosciences shares in Q2 2022, an estimated $80.9M.
Alphabet Inc first reported a position in Arcus Biosciences in Q1 2018 and held it in 17 quarters.
Alphabet Inc's Arcus Biosciences position peaked at $143M in Q3 2021.
173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on Alphabet Inc's 13F filing for Q2 2022, filed 15 Nov 2022.